Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera.

Nagele E, Han M, Demarshall C, Belinka B, Nagele R.

PLoS One. 2011;6(8):e23112. doi: 10.1371/journal.pone.0023112. Epub 2011 Aug 3.

2.

Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera.

Han M, Nagele E, DeMarshall C, Acharya N, Nagele R.

PLoS One. 2012;7(2):e32383. doi: 10.1371/journal.pone.0032383. Epub 2012 Feb 22.

4.

Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown.

Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, Nagele RG.

Brain Res. 2010 Jul 23;1345:221-32. doi: 10.1016/j.brainres.2010.05.038. Epub 2010 Jun 11.

PMID:
20546711
5.

Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age.

Dicou E, Vermersch P, Penisson-Besnier I, Dubas F, Nerrière V.

Autoimmunity. 1997;26(3):189-94.

PMID:
9550286
6.

Serum-autoantibodies for discovery of prostate cancer specific biomarkers.

Massoner P, Lueking A, Goehler H, Höpfner A, Kowald A, Kugler KG, Amersdorfer P, Horninger W, Bartsch G, Schulz-Knappe P, Klocker H.

Prostate. 2012 Mar;72(4):427-36. doi: 10.1002/pros.21444. Epub 2011 Jul 11.

PMID:
22012634
7.

A gene expression pattern in blood for the early detection of Alzheimer's disease.

Booij BB, Lindahl T, Wetterberg P, Skaane NV, Sæbø S, Feten G, Rye PD, Kristiansen LI, Hagen N, Jensen M, Bårdsen K, Winblad B, Sharma P, Lönneborg A.

J Alzheimers Dis. 2011;23(1):109-19. doi: 10.3233/JAD-2010-101518.

PMID:
20930264
8.

Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.

DeMarshall CA, Han M, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL, Kosciuk M, Thayasivam U, Belinka B, Nagele RG; Parkinson’s Study Group Investigators.

Immunol Lett. 2015 Nov;168(1):80-8. doi: 10.1016/j.imlet.2015.09.010. Epub 2015 Sep 16.

9.

Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease.

Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S.

J Alzheimers Dis. 2010;21(2):585-96. doi: 10.3233/JAD-2010-100279.

PMID:
20571216
10.

Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease.

Fehlbaum-Beurdeley P, Sol O, Désiré L, Touchon J, Dantoine T, Vercelletto M, Gabelle A, Jarrige AC, Haddad R, Lemarié JC, Zhou W, Hampel H, Einstein R, Vellas B; EHTAD/002 study group.

J Alzheimers Dis. 2012;32(1):169-81.

PMID:
22785402
11.

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K.

Neurobiol Aging. 2008 Jul;29(7):961-8. Epub 2007 Feb 23.

PMID:
17321007
12.

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.

DeMarshall CA, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL, Kosciuk M, Thayasivam U, Han M, Belinka B, Nagele RG; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (Amst). 2016 Apr 12;3:51-62. doi: 10.1016/j.dadm.2016.03.002. eCollection 2016.

13.

Serum biomarkers for Alzheimer's disease: proteomic discovery.

German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP.

Biomed Pharmacother. 2007 Aug;61(7):383-9. Epub 2007 Jun 18.

PMID:
17614251
14.

A novel blood test for the early detection of Alzheimer's disease.

Rye PD, Booij BB, Grave G, Lindahl T, Kristiansen L, Andersen HM, Horndalsveen PO, Nygaard HA, Naik M, Hoprekstad D, Wetterberg P, Nilsson C, Aarsland D, Sharma P, Lönneborg A.

J Alzheimers Dis. 2011;23(1):121-9. doi: 10.3233/JAD-2010-101521.

PMID:
20930265
15.

Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls.

McIntyre JA, Wagenknecht DR, Ramsey CJ.

Autoimmunity. 2009;42(8):646-52. doi: 10.3109/08916930903074833.

PMID:
19886736
16.

Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease.

Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ.

J Alzheimers Dis. 2011;24(1):47-59. doi: 10.3233/JAD-2010-101722.

PMID:
21157020
17.

Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers.

Tan M, Wang S, Song J, Jia J.

Neurosci Lett. 2012 May 16;516(2):226-31. doi: 10.1016/j.neulet.2012.03.093. Epub 2012 Apr 6.

PMID:
22503900
18.

Identification of a blood-based biomarker panel for classification of Alzheimer's disease.

Laske C, Leyhe T, Stransky E, Hoffmann N, Fallgatter AJ, Dietzsch J.

Int J Neuropsychopharmacol. 2011 Oct;14(9):1147-55. doi: 10.1017/S1461145711000459. Epub 2011 Apr 5.

PMID:
21466745
19.

A relationship between Alzheimer's disease and type 2 diabetes mellitus through the measurement of serum amyloid-beta autoantibodies.

Kim I, Lee J, Hong HJ, Jung ES, Ku YH, Jeong IK, Cho YM, So I, Park KS, Mook-Jung I.

J Alzheimers Dis. 2010;19(4):1371-6. doi: 10.3233/JAD-2010-1332.

PMID:
20061608
20.

Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression.

Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D, Carrière J, Guihal C, Soucaille C, Rouet F, Drouin D, Sol O, Jordan H, Wu D, Lei L, Einstein R, Schweighoffer F, Bracco L.

Alzheimers Dement. 2010 Jan;6(1):25-38. doi: 10.1016/j.jalz.2009.07.001.

PMID:
20129318

Supplemental Content

Support Center